MSD applies for ‘Zepatier’ approval, expecting competition among hepatitis C therapies
Another oral hepatitis C treatment seems to be introduced in Korea.
According to the industry concerned on the 26th, MSD turned in approval application of a new oral direct acting antiviral, ‘Zepatier(elbasvir+grazoprevir).’ It is expected to be approved within this year.
The drug is a comple...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
